UTI - Healthcare Fund

A Sectoral/Thematic Fund scheme from UTI Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF789F01TO9).

NAV ₹399.3539 on 16 November 2026.

Expense ratio

Total expense ratio 1.33% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 1.04%, brokerage 0.03%, transaction costs 0.00%, statutory levies including GST 0.26%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year21.8%13.8%-10.2%1.081.11
3 years23.8%13.7%-15.9%1.231.16
5 years17.2%13.3%-19.4%0.770.74
10 years15.9%15.2%-22.6%0.590.57

Category rank: 3rd of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (September 2026 disclosure). Company shares make up 94.2% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 7.62%
  2. Divi's Laboratories Limited — 6.15%
  3. NET CURRENT ASSETS (cash) — 5.85%
  4. Dr. Reddy's Laboratories Limited — 5.24%
  5. Ajanta Pharma Limited — 4.81%
  6. Gland Pharma Limited — 4.06%
  7. Alkem Laboratories Limited — 3.70%
  8. Apollo Hospitals Enterprise Limited — 3.03%
  9. Caplin Point Laboratories Limited — 3.02%
  10. Global Health Limited — 2.96%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.